The effectiveness of prophylactic TNF neutralization treatment in ICB therapy was linked to a higher abundance of infiltrated antigen-specific CD8+ T cells in the tumor microenvironment and tumor-draining lymph nodes (dLN) with the presence of gp70- and OVA-positive CD8+ T cells in MC38 and B16-OVA mouse models, respectively. This evidence concerns the gene CD8A and neoplasm.